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E-mail: schung8@nymc.eduDuring development, cortical interneurons (cINs) are gener-
ated from the ventral telencephalon, robustly migrate to the
dorsal telencephalon, make local synaptic connections, and
critically regulate brain circuitry by inhibiting other neurons.
Thus, their abnormality is associated with various brain disor-
ders. Human pluripotent stem cell (hPSC)-derived cINs can
provide unlimited sources with which to study the pathogenesis
mechanism of these disorders as well as provide a platform to
develop novel therapeutics. By employing spinner culture, we
could obtain a >10-fold higher yield of cIN progenitors
compared to conventional culture without affecting their
phenotype. Generated cIN spheres can be maintained feeder-
free up to 10 months and are optimized for passaging and
cryopreservation. In addition, we identiﬁed a combination of
chemicals that synchronously matures generated progenitors
into SOX6+KI67 migratory cINs and extensively character-
ized their maturation in terms of metabolism, migration,
arborization, and electrophysiology. When transplanted into
mouse brains, chemically matured migratory cINs generated
grafts that efﬁciently disperse and integrate into the host
circuitry without uncontrolled growth, making them an
optimal cell population for cell therapy. Efﬁcient large-scale
generation of homogeneous migratory cINs without the need
of feeder cells will play a critical role in the full realization of
hPSC-derived cINs for development of novel therapeutics.
INTRODUCTION
Cortical interneurons (cINs), especially those subtypes that express
parvalbumin (PV), and somatostatin (SST), are derived from the
medial ganglionic eminence (MGE) in the subpallium during early
development. They migrate all the way to the dorsal telencephalon,
where they make local synaptic connections with excitatory glutama-
tergic neurons and critically regulate local brain circuitry by releasing
the inhibitory neurotransmitter g-aminobutyric acid (GABA).1,2414 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2
This is an open access article under the CC BY-NC-ND license (httpCompromised function of these cINs is associated with various brain
disorders, such as schizophrenia, autism, and epilepsy.3,4 Furthering
our understanding of the cIN-associated disease pathogenesis mech-
anism depends on securing relevant tissue sources for analysis.
Obtaining relevant brain tissues during the pathogenesis process
was once extremely challenging with the exception of end-stage post-
mortem tissues or rare resected patient brain tissues. However, it is
now possible to generate disease-relevant tissues in unlimited quan-
tity with exactly the same genetic makeup as the patient with the
development of induced pluripotent stem cell (iPSC) technology,5
as long as efﬁcient ways to generate a homogeneous population of
speciﬁc progenies can be identiﬁed.
Not only do they provide clues to normal and abnormal develop-
mental process in health and disease, but human PSC-derived neu-
rons can also serve as a source of cells for cell-replacement therapy,
allowing treatment of brain disorders for patients without other effec-
tive treatment options.6–12 In particular, iPSC-derived neuronal
progenies could provide autologous cell sources for cell replacement
without the need for immunosuppression or concerns over immune
rejection. Cell transplantation, especially transplantation of cINs, was
shown to provide improvement of symptoms in diverse preclinical
models of CNS disorders such as epilepsy, Parkinson’s disease, neuro-
pathic pain, schizophrenia, and cognitive deﬁcits.6,13–16 Transform-
ing these promising preclinical studies into a clinical reality critically
depends on the ability to generate large quantities of homogeneous
cell populations that are in the optimal stage of development for
therapeutic use.019 ª 2019 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Optimization of Large-Scale Generation of MGE cIN Progenitors
(A) Scheme of MGE progenitor phenotype induction from hPSCs. White scale bar, 5 mm. Yellow scale bar, 200 mm. (B) Spinner culture efficiently generated H9 MGE
progenitor populations in large quantities. Spheres under different culture conditions were trypsinized at the end of week 3 for cell counting. One-way ANOVA (p < 0.001)
followed by Tukey post-hoc analysis was performed to analyze the relative changes in total cell numbers and sphere sizes (Table S3). Data are presented as mean ± SEM
(legend continued on next page)
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Molecular Therapy: Methods & Clinical DevelopmentMGE progenitors and cINs have been derived from human plurip-
otent stem cells (hPSCs) either by activating the developmentally
relevant signaling pathways during differentiation6,17–19 or by direct
induction using exogenous expression of fate-inducing transcrip-
tion factors.20–22 However, large-scale generation of cINs that can
meet the demand of translational and clinical use for disease
modeling, drug screening, and/or cell therapy have not been demon-
strated. Protracted maturation of human cINs requires more time in
culture to achieve the proper maturation for disease modeling or cell
therapy. Most of these methods involve coculture with other cell
types such as astrocytes or glutamatergic neurons to support long-
term maturation and maintenance in vitro,17,19,20,22 yielding
mixtures of cell populations with variable functional properties.
This is not optimal for transcriptome analysis or cell therapy use
and awaits a more homogeneous culture system that supports
long-term culture. In addition, hPSC-derived neuronal progenies
are usually asynchronous, composed of proliferating progenitors
and postmitotic neurons at the same time (just as during normal
development); such stochasticity and heterogeneity always raises
the concern of unreliable assays for disease modeling23 and graft
safety for cell therapy.24,25 Protracted maturation of the cINs them-
selves is a hurdle in the efﬁcient use of cINs for various assays,
raising the cost and time required before attaining a reasonable
maturation status for utilization and assay. This requires the devel-
opment of a method that can synchronously facilitate the matura-
tion of cINs, preferably without genetic modiﬁcations that pose
the risk of insertional mutagenesis that can compromise both
disease study and cell therapy.
In this study, we addressed the major issues that are in the way of efﬁ-
cient application of hPSC-derived cINs to further our knowledge in
disease pathogenesis and to develop novel therapeutics. We opti-
mized spinner culture of three-dimensional (3D) cIN spheres to
support the industrial-scale generation of homogeneous cIN popula-
tions. This feeder-free culture system sustained generated cINs in the
long term without compromising their survival or phenotype and
was optimized for passaging and cryopreservation with the incorpo-
ration of Trehalose. Moreover, we have optimized their synchro-
nized maturation into early postmitotic migratory cINs using a
cocktail of chemicals, conﬁrming their maturation in terms of meta-
bolism, migration, arborization, and electrophysiology. Further-
more, chemical treatment of hPSC-derived MGE cells was efﬁcient
in controlling proliferation in the grafts after transplantation into
Nod Scid mouse brains and promoting migration and integration
of grafted cells in the host brains. This efﬁcient method will bring
clinical translation of cIN cell therapy closer to reality by providing
translation-ready homogeneous cINs of the proper developmental
stage for optimal grafting.(n = 6–9 independent differentiations). (C and D) Spinner culture maintained the MGE p
and analyzed for the MGE progenitor phenotype (NKX2.1+) by immunocytochemistry (C
independent differentiation). For the comparison of NKX2.1+ cells, one-way ANOVA (p =
generated cINs 6 weeks after differentiation, analyzed by immunocytochemistry (E) an
independent differentiation). One-way ANOVA was performed for SOX6 (p = 0.174), G
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Optimization of Large-Scale Generation of MGE cIN Progenitors
In our previous study, we developed a protocol to generate homoge-
neous populations of cINs from hPSCs based on ventral speciﬁcation
of sphere or organoid culture.18,26 For efﬁcient use of hPSC-derived
cINs, it is imperative to derive them in a scale large enough for indus-
trial use in drug screening or cell therapy. Thus, we tested the effect of
different methods of culture on the expansion and generation ofMGE
progenitors. The MGE progenitor cells were induced for three weeks
according to our previous reports14,18 with slight modiﬁcations
(Figure S1A). After the establishment of sphere cultures under static
conditions for a week, we tested three different culture conditions
(static, shaker, and spinner) for 2 weeks. Spinner culture generated
signiﬁcantly greater increases in total cell numbers compared to static
and shaker cultures (Figures 1A and 1B; Table S3). This is possibly
due to more efﬁcient air, nutrient, and waste exchange in the spinner
system. Spinner culture also resulted in more homogeneous sphere
sizes, without the random adhering of spheres that can cause spheres
to become too big for efﬁcient air, nutrient, and waste exchange (Fig-
ures 1A and 1B; Table S3). Next, we examined the phenotype of
generated cells in each culture condition to rule out the possibility
that spinner culture favors the induction or expansion of alternate
phenotype cells with a faster growth rate than MGE progenitors.
Despite massive expansion, cells grown in spinner culture also
showed a homogeneous MGE progenitor phenotype shown by
uniform NKX2.1 expression (Figures 1C and 1D). When further
differentiated, cells from spinner culture generated homogeneous
populations of cINs shown by uniform expression of SOX6, GAD1,
and bIII-TUBULIN either as sphere cultures (Figures 1E and 1F) or
after transferring to adherent cultures (Figure S1B). Some of the
generated cINs expressed subtype-enriched markers such as
MEF2C, SST, COUPTFII, and vasoactive intestinal polypeptide
(VIP) (Figure S1C). There were very few other neural cells generated
such as astrocytes (GFAP+), oligodendrocytes (OLIG2+), cholinergic
neurons (ChAT+), serotonergic neurons (5HT+), dopaminergic neu-
rons (TH+), or glutamatergic neurons (Glutamate+) (Figure S1C).Long-Term Organoid Culture of cINs
Long-term culture of cINs was previously achieved by coculturing
with the feeder cells such as astrocytes and glutamatergic neu-
rons.17,19,20,22 While feeder cells enable the long-term culture of
generated human cINs, they may not be optimal for disease modeling
or cell therapy. Thus, we tested whether we could maintain a homo-
geneous population of MGE cells as cIN spheres on a long-term basis
without compromising the viability of the cINs. MGE spheres were
maintained as spinner cultures for 6 weeks and then transferred to
static culture to avoid shearing of organoids (Figure 2A). After 4 weeksrogenitor phenotype. Cells were plated onto coverslips after 3 weeks’ differentiation
) and cell counting (D). Scale bars, 50 mm. Data are presented as mean ± SEM (n = 3
0.171) was performed. (E and F) MGE progenitors induced under different conditions
d cell counting (F). Scale bars, 50 mm. Data are presented as mean ± SEM (n = 3
AD1 (p = 0.708), and bIII-TUBULIN expression (p = 0.541).
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Figure 2. Long-Term Culture and Passaging of cIN Organoids
(A) Long-term culture scheme for the generation of cIN organoids. (B) Immunohistochemistry analysis of H9 cIN organoids after 4 weeks’ differentiation for the MGE progenitor
phenotype (NKX2.1, NESTIN, and SOX2) and cIN phenotype (pan-DLX). Scale bars, 100 mm. (C) Immunohistochemistry analysis of cIN organoids after 24 weeks’ differentiation
for theMGEprogenitormarker (NKX2.1), cINmarkers (GABAandpan-DLX), early postmitotic neuronalmarker (DCX), and apoptosismarker (activeCASPASE3).White scale bars,
100 mm. (D) Real-time PCR analysis of 4-week-old versus 40-week-old cIN organoids. Data are presented asmean± SEM (n = 3 independent differentiation). For the comparison
of gene expression, one-way ANOVA was performed for KI67 (p = 0.027), GAD1 (p = 0.048), SOX6 (p = 0.003), DLX2 (p < 0.001), LHX6 (p = 0.022), and SST (p = 0.001). The
results of the Tukey post-hoc analysis are summarized in Table S4. (E) Trehalose efficiently increased the viability of the cINs during organoid passaging. Data are presented as
mean ± SEM (n = 4 independent differentiation). Analysis was done using a two-tailed unpaired t test (p = 0.006 for 6 weeks and p = 0.037 for 24 weeks).
www.moleculartherapy.org
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Figure 3. Combined Chemical Treatment Significantly Reduce Proliferating Progenitor Cells in cIN Culture
(A) Immunohistochemistry analysis of KI67+ proliferating progenitors in H9 cIN organoids 24 weeks after differentiation. Yellow scale bars, 50 mm. (B) Chemical treatment
scheme for MGE progenitors. (C and D) Immunocytochemistry (C) and cell-counting analysis (D) of KI67+-proliferating MGE progenitors after treatment with different
chemicals for 1 week. Scale bars, 50 mm. For comparison of the proportion of proliferating cells, one-way ANOVA (p < 0.001) followed by Tukey post-hoc analysis was
performed (Table S5). Data are presented as mean ± SEM (n = 4 independent differentiation). (E) Immunocytochemistry analysis of 6-week-old cINs treated with CDP for
(legend continued on next page)
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www.moleculartherapy.orgof organoid culture, many cells expressed MGE progenitor markers,
such as NKX2.1, NESTIN, and SOX2 (Figure 2B), whereas the
proportion of pan-DLX+ cells was relatively low. In MGE spheres
after 24 weeks of culture, there were less NKX2.1+ cells but more cells
expressed the markers that are enriched in post-mitotic cINs such as
GABA, pan-DLX, and DCX (Figure 2C). Spheres at 24 weeks of
culture were still healthy without much sign of apoptosis (Figure 2C).
We also quantitatively analyzed the changes in gene expression level
as the cIN spheres matured by real-time PCR. Signiﬁcant decreases in
the expression of proliferating cell marker KI67 were observed as cIN
spheres matured, whereas the expression of postmitotic cIN markers
GAD, SOX6, DLX2, LHX6, and SST were signiﬁcantly higher in
40-week-old cIN spheres compared to 4-week-old spheres (Figure 2D;
Table S4).
One of the barriers of utilizing organoid culture for long-term main-
tenance of cINs is the difﬁculty of passaging older spheres or organo-
ids, as they develop thick networks of neurites just as during normal
brain development. Since it was reported that Trehalose could
signiﬁcantly improve cell viability after dissociation of neurons in
mature mouse brains,27 we tested the effect of Trehalose on the disso-
ciation of tightly knit older spheres. Trehalose treatment during
passaging signiﬁcantly increased cell survival 6 weeks after differenti-
ation. The increase in survival was much more pronounced in older
spheres or organoids after 6 months’ differentiation (Figure 2E).
Optimized passaging of older spheres or organoids will enable the
efﬁcient utilization of cINs that are maintained long-term and
feeder-free.
Combined Chemical Treatment Significantly Reduces
Proliferating Progenitor Cells in cIN Culture
One thing we noticed in long-term organoid culture was the presence
of proliferating cells (KI67+) even 24 weeks after differentiation (Fig-
ure 3A). This population of lingering progenitors could generate
grafts with uncontrolled growth when cells are used for cell therapy
and could confound assays when postmitotic neurons are needed
for disease modeling. Thus, we set out to optimize the culture to a
more mature and postmitotic population, free of lingering prolifer-
ating progenitors. Thus, we treated 3-week-old MGE progenitors
with various candidate chemicals or factors for a week and analyzed
the proportion of proliferating cells (Figure 3B). The antimitotic drug
ﬂuorodeoxyuridine (FdU) did not inﬂuence the proportion of prolif-
erating MGE progenitors, whereas neuronal culture supplement
CultureOne, gamma secretase inhibitor N-[N-(3,5-diﬂuorophenace-
tyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), or CDK4/6
inhibitor PD0332991 signiﬁcantly reduced the proportion of prolifer-
ating progenitors. Furthermore, combined treatment of the three
working chemicals (termed CDP) further decreased proliferating cells
(Figures 3C and 3D; Table S5). As expected, the decrease in the pro-0, 1, and 3 weeks. Scale bars, 50 mm. (F) Cell-counting analysis. One-way ANOVA (p =
cells after CDP treatment for 1 week (p < 0.001) and 3 weeks (p < 0.001) compared to the
groups for SOX6+ cells (p = 0.985), GAD1+ cells (p = 0.931), bIII-TUBULIN + cells (p = 0
(n = 5 independent differentiation).
Moleculportion of proliferating cells was accompanied by a decrease in total
cell number 1 week after CDP treatment (Figure S3). Extending CDP
treatment to 3 weeks further reduced the proportion of proliferating
progenitors compared to 1 week’s treatment (Figures 3E and 3F;
Table S6). The CDP treatment does not affect the phenotypes of
treated cell populations (SOX6+, GAD+, and bIII-TUBULIN+) or
cell death even after 3 weeks’ chemical treatment (Figures 3E and 3F).
Combined Chemical Treatment Facilitates the Synchronized
Maturation of cIN Cultures
hPSC-derived cINs go through protracted maturation, recapitulating
development in vivo.18,19 Facilitating maturation to the proper stage
will be important for efﬁcient use of hPSC-derived cINs for disease
modeling and cell therapy. To identify maturation parameters of
cINs during development, we analyzed genes that are differentially
expressed during their in vivo development, comparing cINs from
E13.5 to adult brains.28,29 One of the most striking changes during
maturation of cINs in mouse brains was the signiﬁcant upregulation
of genes that regulated metabolism (Figures 4A and S4A). This devel-
opmental change makes sense, considering the high-energy demand
of mature cINs. Thus, we analyzed metabolic maturation of cINs
with or without CDP treatment using a seahorse analyzer (Figures
4B and S4B). CDP-treated cINs showed signiﬁcant increase in
oxidative phosphorylation, especially in basal respiration and ATP
production (Figure 4C; Table S7).
During normal development of cINs, they migrate extensively from
the MGE all the way to the dorsal telencephalon, where they make
local synaptic connections and regulate local circuitry.30 Thus, we
tested whether CDP treatment can facilitate the transformation of
MGE progenitors into actively migrating postmitotic cINs. Thus,
we embedded 9-week-old cIN organoids in a Geltrex matrix with
or without CDP treatment and analyzed their migratory properties
7 days after embedding (Figures 5A and 5B). There was a signiﬁcant
increase in migratory cINs by CDP treatment compared to untreated
cells (Figures 5B and S5A).
As another criterion of maturation, we analyzed whether CDP treat-
ment affects arborization of cINs. Three-week-old cINs were plated
on coverslips and labeled only scarcely with a limiting titer of
lentivirus that expresses GFP under the ubiquitin promoter
(LV-Ubi-GFP). Arborization of CDP-treated or untreated cINs was
analyzed after 3 weeks’ CDP treatment (Figure 5A). There was a sig-
niﬁcant increase of arborization with CDP treatment (Figures 5C and
S5B), shown by the increase in total neurite length and total branch
numbers.
Next, we analyzed the electrophysiological maturation of cINs by
whole-cell patch-clamp after 9 weeks’ CDP treatment (Figure 5A).0.001), followed by Tukey post-hoc analysis showed a significant decrease in KI67+
control group (Table S6). One-way ANOVA showed no significant difference among
.896), and active CASPASE3+ cells (p = 0.789). Data are presented as mean ± SEM
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AB
C
Figure 4. CDP Treatment Facilitates Metabolic Maturation of cINs
(A) DAVID analysis of genes with large differences in relative ranked expression between purified mouse cINs from E13.5 versus cINs from adult brain, showing significant
changes in the metabolism pathway. (B) Analysis scheme for the metabolic maturation of cINs after CDP treatment. (C) CDP treatment significantly enhanced the metabolic
maturation of H9 cINs. Data are presented as mean ± SEM (n = 10 wells) using paired one-way ANOVA. The Tukey post-hoc analysis was listed in Table S7.
Molecular Therapy: Methods & Clinical DevelopmentCDP-treated cINs showed more mature membrane properties,
including higher resting membrane potential (RMP), lower mem-
brane resistance (Rm), and higher membrane capacitance (Cm). Of
the cells recorded, a majority of cINs ﬁred action potentials (APs),
with an increased proportion of AP-ﬁring neurons among those
treated with CDP. CDP treatment also decreased AP threshold, but
there was no signiﬁcant difference in the parameters of AP ﬁring,
such as AP half width and afterhyperpolarization (AHP) (Figure S5C).
We also analyzed 6-week-old cINs with 3 weeks’ CDP treatment. The420 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2maturation of electrophysiological properties by CDP treatment was
signiﬁcant even at this time point (Figure S5D), with higher RMP,
lower Rm, and higher Cm.
CDP-Treated cINs Generate Safe and Well-Integrating Grafts
after Transplantation into Nod Scid Mouse Cortex
To further test the hypothesis that CDP-treated cINs will provide
optimal populations for cell transplantation, we grafted 4-week-old
cINs with or without a week of CDP treatment to Nod Scid mouse019
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Figure 5. CDP Treatment Enhances Migratory, Morphological, and Electrophysical Maturation
(A) Analysis scheme for migration, arborization, and electrophysiology of cINs. (B) CDP treatment significantly increased the migration of generated iPSC cINs. cIN organoids
were embedded in a Geltrex matrix at 9 weeks of differentiation with or without CDP treatment and analyzed for migration 7 days after embedding. White scale bars, 200 mm;
yellow scale bars, 100 mm. Data are presented as mean ± SEM (n = 3 independent spheres). Analysis was done using a two-tailed unpaired t test (p = 0.019 for cells in the
spheres, p = 0.008 for cells with migration distance of 0–400 mm, and p = 0.001 for cells with migration distance > 400 mm). (C) CDP treatment significantly enhanced
(legend continued on next page)
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Molecular Therapy: Methods & Clinical Developmentcortices and analyzed the grafts 1 month after transplantation (Fig-
ure 6A). Both untreated and CDP-treated cells generated grafts
enriched with the MGE-derived cIN phenotype shown by ubiquitous
expression of GABA and SOX6 (Figures 6B and 6C). Whereas there
were still a number of KI67+ proliferating cells in untreated grafts,
such cells were rarely observed in CDP-treated cell grafts (Figures 6D
and 6E). Consistent with having more proliferating cells in untreated
cell grafts, the total graft cell numbers were signiﬁcantly higher in
untreated cell grafts compared to CDP-treated cell grafts (Figure 6E).
This result gives conﬁdence that CDP-treated cINs will generate safe
grafts in the host brain without uncontrolled proliferation.
In addition, many more migrating cells were observed outside the
graft core in CDP-treated cell grafts, whereas very few such cells
were observed in untreated cell grafts at this time point (Figures 6D
and 6F). Next, we tested the hypothesis that the CDP-treated cells,
being more mature, would result in more efﬁcient synapse formation
of grafted cINs. Thus, we analyzed inhibitory synapse formation of
grafted cINs by triple staining the grafted brains with antibodies
against human-speciﬁc neural cell adhesion molecule (NCAM),
inhibitory presynaptic marker vesicular GABA transporter
(VGAT), and inhibitory postsynaptic marker Gephyrin. We then
analyzed VGAT+NCAM+ puncta that were juxtaposed with
Gephyrin+ puncta using IMARIS software. There was a signiﬁcant
increase in inhibitory synapse formation among CDP-treated cINs
in the host cortex compared to untreated cINs (Figures 6G and S6),
suggesting CDP-treated cINs will provide cell populations for optimal
integration into host circuitry.
Optimization of Cryopreservation of hPSC-Derived cINs
Considering the long-term culture required for cIN generation from
hPSCs, the ability to freeze down and store intermediate progenies of
differentiation will greatly enhance the efﬁciency of their utilization. It
was reported that Trehalose could help pluripotent stem cells or other
stem cells survive during cryopreservation.27,31,32 Thus, we tested
whether inclusion of Trehalose during cryopreservation of cINs can
improve their viability (Figure 7A). Trehalose indeed signiﬁcantly
increased survival of cryopreserved cINs after freeze-thaw (Figure 7B)
without affecting their phenotypes (Figures 7C and 7D). Under the
optimized conditions, the majority of cINs maintained viability dur-
ing cryopreservation under our optimized condition (65.27% ± 8.97%
compared to the cINs passaged without cryopreservation). The
phenotype of the cells was also well preserved during freeze-thaw
cycles (Figures 7E and 7F).
DISCUSSION
Reliable and efﬁcient generation of human cINs from hPSCs in large
scale will be critical for further understanding interneuron-relatedarborization of H9 cINs. Number of neurites from soma (p = 0.180), branch numbers (p =
Data are presented as mean ± SEM (n = 12 neurons). (D) CDP treatment significantly e
Data are presented as mean ± SEM (n = 24 control neurons and n = 28 CDP-treated n
potential (RMP; p = 0.041), membrane resistance (Rm; p = 0.001) andmembrane capac
action potential firing (Chi-square test; p = 0.001) with significant increase of AP thresh
422 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2brain disorders and the development of novel therapeutics. The fact
that many therapeutics developed in animal models failed in human
clinical trials33,34 has raised the need to utilize real human tissues to
develop novel therapeutics. In addition, large-scale reproducible
generation of human cINs from hPSCs will be critical to the clinical
realization of cell replacement therapy for interneuron-related disor-
ders such as epilepsy, where novel therapeutics are desperately
needed, especially for treatment-refractory patients. Previous studies
provide a number of methods for generating cINs from hPSCs with
varying efﬁciencies, some using genetic modiﬁcation20–22 and others
by providing developmentally relevant signaling molecules.6,17–19
However, large-scale generation of cINs that can support efﬁcient
drug screening and cell-transplantation therapy has not been re-
ported so far. In this study, we have tested different methods of
deriving MGE spheres and identiﬁed that spinner culture supports
the generation of > 10-fold more MGE cells compared to the conven-
tional static culture. The large increase was not due to overgrowth of
irrelevant cell types, as we conﬁrmed through immunocytochemical
analysis, but more effective removal of cellular waste from the micro-
environment surrounding spheres and efﬁcient delivery of nutrients
and oxygens by constant stirring. It was still surprising to observe a
much greater generation of MGE cells compared to shaker culture,
which is often used as an analogous method in many organoid
cultures.35–38 One thing we noticed was that using shaker culture,
the spheres tended to adhere to each other and formed much larger
clusters. This is likely due to centripetal force that tends to keep
most of the spheres near the center of the ﬂasks, whereas spheres
from spinners form smaller and more homogeneous spheres, likely
due to the shearing forces generated by the stirring motion. Thus, it
is possible that the much larger size of shaker-based spheres pre-
vented efﬁcient circulation within spheres (removal of waste and
delivery of nutrients and oxygen), whereas smaller and homogeneous
spheres from spinners were more efﬁcient.
To facilitate the maturation of MGE cells, we tested a series of agents
that were implicated in cell cycle exit and maturation of neural cell
types.39–42 The antimitotic drug FdU was not effective in reducing
immature proliferating cell numbers in MGE cell preparation.
However, CultureOne supplement (Life Technologies), which is
used to increase neuronal maturation, was effective in increasing
the cell cycle exit of MGE cells. The gamma secretase inhibitor
DAPT, which inhibits notch signaling and thus reduces neuronal
progenitor proliferation42–44 also worked well to control the cell cycle
exit of MGE cells. The cyclin-dependent kinase 4/6 (CDK4/6) inhib-
itor PD0332991, which facilitates the cell cycle exit of proliferating
neuronal progenitors41 was also effective in regulating MGE cell cycle
exit. A combination of the last three chemicals was more effective in
inducing the synchronous maturation of MGE cells than any single0.001), and neurite lengths (p = 0.005) were analyzed by two-tailed unpaired t test.
nhanced the electrophysiological maturation of cINs after 9 weeks’ CDP treatment.
eurons). Analysis was done using a two-tailed unpaired t test for resting membrane
itance (Cm; p < 0.001). CDP treatment generated a higher proportion of neurons with
old (p = 0.046).
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Figure 6. Transplantation Analysis of CDP-Treated cINs after Transplantation into Nod Scid Mouse Cortex
(A) Scheme of transplantation analysis. cINs with or without 1 week’s CDP treatment were transplanted into the cortex of Nod Scid mice, and grafts were analyzed 1 month
after transplantation. (B and C) Untreated or CDP-treated H9 cells generate grafts enriched with MGE-type cINs, as shown by immunohistochemistry analysis using anti-
GABA antibody (B) and anti-Sox6 antibody (C). White scale bars, 50 mm, and yellow scale bars, 25 mm. (D) CDP-treated cINs generated grafts with a lower proportion of
proliferating cells, as analyzed by immunohistochemistry using antibodies against human-specific NCAM and KI67. The white dotted linesmark the graft borders. Scale bars,
100 mm. (E) CDP treatment significantly decreased the proportion of proliferating cells in the graft 1 month after transplantation (p < 0.001) and the total graft cell numbers
(p = 0.049). Data are presented as mean ± SEM (n = 4). Analysis was done using a two-tailed unpaired t test. (F) Migration analysis of grafted cINs. Data are presented as
mean ± SEM (n = 3). Analysis was done using a two-tailed unpaired t test (p = 0.002 for cells in graft core, p = 0.008 for cells with migration distance 0–100 mm, and p = 0.001
for cells withmigration distance > 100 mm). (G) Analysis of inhibitory GABAergic synapses in grafted cINs 1month after transplantation. Scale bar, 5 mm.Data are presented as
mean ± SEM (n = 5). Analysis was done using a two-tailed unpaired t test (p < 0.001).
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Figure 7. Cryopreservation of MGE Progenitors
(A) Analysis scheme of MGE progenitor cryopreservation. (B) Trehalose in freezing media increased the H9 cIN survival during cryopreservation. cIN progenitors were
trypsinized after 3 weeks’ differentiation, and the same number of cells were frozen with or without Trehalose in freezing media. Total cell numbers were counted after
(legend continued on next page)
Molecular Therapy: Methods & Clinical Development
424 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019
www.moleculartherapy.orgtreatment with each chemical alone. Previously, genetic modiﬁcation
has been used to facilitate MGE phenotype induction or faster matu-
ration.20–22 However, genetic modiﬁcation methods need to be used
with caution for studying diseases with complex genetics such as
schizophrenia, where hundreds of common variants (single nucleo-
tide polymorphisms [SNPs]) work together to cause the phenotype.45
Thus, a method that could change the SNP landscape would not be
desirable. Furthermore, more caution will be needed to generate
clinical-grade cell populations for the purpose of cell therapy to avoid
potential insertional mutations in the grafted cells. Other studies
employed feeder coculture such as astrocytes or glutamatergic neu-
rons for better maturation and maintenance.17,19,20,22 Feeder-based
cultures also could hinder analysis where a pure population is more
desirable (such as transcriptome analysis applications) and may not
be optimal, especially for clinical applications that require xeno-free
preparation of cells. Thus, in this study, we used a chemical combina-
tion without the use of genetic modiﬁcation or feeder coculture to
facilitate the functional maturation of cINs (metabolism, migration,
arborization, and electrophysiology). Such enhanced maturity will
be important for both drug-screening purposes and to reduce the
time, cost, and effort necessary to generate cell populations sufﬁ-
ciently mature for assays. In addition, as shown in this study, this
enhanced maturation will also be critical to avoid uncontrolled
growth of proliferating cells in grafts and better integration of grafted
cells into the host brain with superior migration, arborization, and
synaptic connection. One caveat is that although we observed en
masse “maturation” of cINs in diverse physiological aspects, we
cannot distinguish whether we promote maturation from “prolifer-
ating MGE progenitors” to “postmitotic” cINs only or also matura-
tion from “immature cINs” to “more mature cINs.” This could be
addressed by employing single-cell RNA-seq in the future.
It is well-known that human cINs derived from hPSCs are undergo-
ing protracted maturation comparable to their in vivo developmental
timeline. Continued maturation has been observed during the culture
of hPSC-derived cINs just as during normal development,18,19 and
our protocol with chemical treatment signiﬁcantly facilitates this
process. Some applications of hPSC-derived cINs, such as modeling
the disease phenotype in adult brains, will require the attainment of
a fully mature phenotype. However, for the purpose of cell therapy,
this type of developing migratory cIN (SOX6+ KI67) will be more
beneﬁcial than completely mature neurons in that (1) completely
mature neurons with elaborate neurites will be more vulnerable to
the passaging and transplantation procedure than developing cINs
and (2) completely mature neurons lack the migratory properties3 weeks’ recovery from cryopreservation as a sphere culture. Data are presented as me
unpaired t test (p < 0.001). (C and D) Trehalose treatment during the freeze-thaw cyc
counting (D). The cINs were analyzed 3 weeks after thawing by immunocytochemistry f
are presented as mean ± SEM (n = 4 independent differentiation). Analysis was done u
p = 0.063). (E and F) The optimized cryopreservation protocol maintained cIN phenoty
tochemistry (E) and cell counting (F). The cINs, 3 weeks after thawing, were analyzed for t
bars, 50 mm. Data are presented as mean ± SEM (n = 4 independent differentiation). Ana
bIII-TUBULIN, p = 0.391).
Moleculnecessary for optimal integration into host circuitry, unlike these
developing early postmitotic cINs. They will also be better suited
for cell therapy compared to more immature progenitors in that (1)
they contain all the machinery to readily integrate into and regulate
host circuitry and (2) they are postmitotic without any more prolifer-
ating cells that would increase the chance of uncontrolled growth of
grafted cells. Overall, in this study, we have shown efﬁcient large-
scale generation of hPSC-derived human cINs with the proper
developmental stage optimal for cell transplantation, and this work
will provide critical tools for efﬁcient use of hPSC-derived cINs for
cell therapy.
MATERIALS AND METHODS
Culture of hPSC and Differentiation into cINs
These study protocols were approved by the New York Medical
College Institutional Review Board. All procedures were performed
in accordance with the institutional review board’s guidelines.
Human embryonic stem cell (hESC) line H9 (WiCell, Madison, WI,
USA, passage 30–50) or iPSC lines 272, 190, and 48346 was main-
tained on Geltrex (Thermo Fisher, Waltham, MA, USA)-coated
plates in Essential 8 medium (Thermo Fisher, Waltham, MA,
USA). ROCK inhibitor (Y27632, 10 mM, ApexBio, Boston, MA,
USA) was added to the culture for 24 h after passaging to prevent sin-
gle-cell-induced cell death of hPSCs. All the chemicals used in this
study were listed in Table S1.
MGE differentiation was initiated by passaging H9 cells as spheres in
low adherent ﬂasks with SRM media (DMEM with 15% knockout
serum replacement [KSR], 2 mM L-glutamine and 10 mM b-mercap-
toethanol [all from Thermo Fisher, Waltham, MA, USA]). ROCK in-
hibitor was also included on the day of differentiation. For the ﬁrst
week, cells were differentiated in SRM LSsgWmedia (the SRMmedia
supplemented with 0.1 mM LDN193189 [Selleck Chem, Houston,
MA, USA], 10 mM SB431452 [Tocris Bioscience, Minneapolis, MN,
USA], 0.1 mM SAG [Selleck Chem, Houston, MA, USA], and 5 mM
IWP2 [Selleck Chem, Houston, MA, USA]). For the second week,
SRM Lsg media (the SRM media was supplemented with 0.1 mM
LDN193189 and 0.1 mM SAG) was used. In the third and fourth
weeks, the media was changed to N2AA media (DMEM/F12 media
with 0.5% N2 supplement [Life Technologies, Woburn, MA, USA],
and 200 mM AA-ascorbic acid [Sigma-Aldrich, Natick, MA, USA]).
For the third week, the N2AA media was supplemented with
0.1 mM SAG and 50 ng/mL FGF8 (ProSpect, Rocky Hill, CT, USA).
At the beginning of the fourth week, the N2AA media wasan ± SEM (n = 4 independent differentiation). Analysis was done using a two-tailed
le did not alter the cIN phenotype, analyzed by immunocytochemistry (C) and cell
or cIN marker expression (SOX6, GAD, and bIII-TUBULIN). Scale bars, 50 mm. Data
sing a two-tailed unpaired t test (SOX6, p = 0.797; GAD, p = 0.128; bIII-TUBULIN,
pe well comparable to the cells without cryopreservation, analyzed by immunocy-
he cIN phenotypes (SOX6, GAD, and bIII-TUBULIN) by immunocytochemistry. Scale
lysis was done using a two-tailed unpaired t test (SOX6, p = 0.743; GAD, p = 0.765;
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Molecular Therapy: Methods & Clinical Developmentsupplemented with 5 ng/mL glial cell line-derived neurotrophic factor
(GDNF) (ProSpect, Rocky Hill, CT, USA), and 5 ng/mL brain-
derived neurotrophic factor (BDNF; ProSpect, Rocky Hill, CT,
USA) (N2AAGB media). From the ﬁfth week, the cells were main-
tained in the B27GB media (DMEM/F12 media with 1% B27 supple-
ment [Thermo Fisher, Waltham, MA, USA], 5 ng/mL GDNF, and
5 ng/mL BDNF). For comparison of different culture conditions, cells
were cultured in the ﬂask as a static culture or shaking on orbital
shaker at 80 rpm (SK-O180-E analog orbital shaker, Scilogex, Rocky
Hill, CT, USA) or using stirrer culture system at 80 rpm (Celstir spin-
ner ﬂask [Wheaton, Millville, NJ, USA] andMultistirrer Digital Series
Magnetic Stirrers (VELP Scientiﬁca Srl, MB Italy). All cell lines were
routinely tested for mycoplasma once a week using a mycoplasma
detection kit (InvivoGen, San Diego, CA, USA).
For passaging cINs, cells were trypsinized by 0.05% trypsin (Thermo
Fisher, Waltham, MA, USA) supplemented with or without 100 mM
Trehalose (Sigma-Aldrich, Natick, MA, USA). After 5 min incubation
at 37C, the spheres were triturated to dissociate the spheres. An equal
volume of DMEMmedia with 10% FBS (Hyclone, Marlborough, MA,
USA) was added to neutralize Trypsin. In addition, Turbo DNase
(2 U/mL, Thermo Fisher, Waltham, MA, USA) was added to help
clear released DNAs from culture. The cells were then kept in the
incubator for additional 15 min to remove any sticky DNA mass
released during trituration. After incubation, the cells were centri-
fuged and resuspended by B27GB media with ROCK inhibitor. To
exclude the dead cell cluster, the resuspended cells were ﬁltered
through a cell strainer cap (35-mm nylon mesh, Corning, NY, USA)
and plated onto a PLO/FN-coated surface (poly-L-ornithine,
15 mg/mL, Sigma-Aldrich, Natick; ﬁbronectin, 10 mg/mL, Thermo
Fisher, Waltham, MA, USA) for the subsequent experiments.
For chemical treatment of cINs, the differentiated progenitors were
seeded on PLO/FN-coated surface at 3 weeks after differentiation,
and cultured in B27GB media without or with each chemical,
20 mM FdU (Sigma-Aldrich, Natick, MA, USA), 1% CultureOne
(C, Thermo Fisher, Waltham, MA, USA), 10 mM DAPT (D, Sigma-
Aldrich, Natick, MA, USA), and 2 mMPD0332991 (P, Sigma-Aldrich,
Natick, MA, US), or with combination of CultureOne, DAPT, and
PD0332991 (CDP) for the time period designated in each ﬁgure.
For cryopreservation, the trypsinized cells were resuspended in
freezing media (fetal bovine serum [FBS] with 10% DMSO) with or
without 100 mM Trehalose and were frozen slowly overnight in an
insulated container at 80C deep freezer. After 24 h, the stocks
were moved to liquid nitrogen storage until further experiments.
Frozen stocks were thawed quickly in a 37C water bath, transferred
to 15 mL conical tubes with 5 mL media, centrifuged, and resus-
pended in B27GB media with ROCK inhibitor for plating and further
experiments.
Immunocytochemistry and Cell Counting
cINs on coverslips were ﬁxed using 4% paraformaldehyde (PFA; Elec-
tronMicroscopy Sciences, Hatﬁeld, PA) for 10 min, washed with PBS,426 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2and used for staining. The spheres at different differentiation stages
were ﬁxed by 4% PFA for 15 min, rinsed with PBS, cryo-protected
in the 30% sucrose (Thermo Fisher, Waltham, MA, USA) overnight
at 4C, mounted on the chuck using the optimum cutting tempera-
ture (OCT) compound (Thermo Fisher, Waltham, MA, USA) and
cryosectioned at 40 mm using a Leica CM1850 cryostat (Leica
Biosystem, Buffalo Grove, IL, USA). Fixed cells or sphere sections
were incubated with blocking and permeablization buffer (PBS with
10% normal serum and 0.1% Triton X-100) for 10 min. The samples
were then incubated in primary antibodies in antibody dilution buffer
(PBS containing 2% normal serum) overnight at 4C. The detailed
information of the antibodies used were listed in Table S2. After
washing with PBS, cells were incubated with ﬂuorescently labeled
secondary antibodies and DAPI (Invitrogen, Waltham, MA, USA)
in antibody dilution buffer for 1 h at room temperature. Following
the PBS wash, the samples were mounted with ﬂuoromount-G
(SouthernBiotech, Birmingham, AL, USA).
Fluorescent images were taken by the EVOS FL auto microscope (Life
Technologies, Carlsbad, CA), Olympus DSU Spinning Disc Confocal
on an IX81 inverted microscope (Olympus, Center Valley, PA, USA),
and Zeiss LSM710 confocal laser-scanning microscopes (Zeiss,
Oberkochen, Gremany).
For cell counting, multi-point function in ImageJ software (Version
1.51p, NIH, Bethesda, MD, USA) was used. Percentage of positive
cells for eachmarker was calculated by dividing by DAPI-stained total
nuclei number from at least three separate biological replicates.
For each staining, a total of at least 500 cells were counted for each
group.
RNA Preparation, Reverse Transcription, and Real-Time PCR
Analysis
Cells were harvested using TRIzol (Thermo Fisher, Waltham, MA,
USA), and total RNAs were prepared according to the manufac-
turer’s protocol. For the reverse transcription, 500 ng total RNA
was ﬁrst reversely transcribed to cDNA using RevertAid H Minus
Reverse Transcriptase (Thermo Fisher, Waltham, MA, USA). The
real-time PCR reaction was carried out in a 96-well format
with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA). The primer information is as follows: KI67
(F 50-TCCTTTGGTGGGCACCTAAGACCTG-30, R 50-TGATGGT
TGAGGTCGTTCCTTGATG-30), GAD (F 50-CTGCTCTTCTCTT
ACGCTCTCTGTC-30, R 50-TCTTCGGAAATGTTGCCTTAGG-30),
SOX6 (F 50-ATCTCTCATCCCGACCCAAGAC-30, R 50-TTCCCA
GGCTTCCTCCAATG-30), DLX2 (F 50-GCCTCAACAACGTCC
CTTACT-30, R 50- GGGAGCGTAGGAGGTGTAGG-30), LHX6
(F 50-ATTCCTTGCGTGGATTATGTGG-30, R 50-TCCGTGTGTGT
GTTTTCCCC-30), SST (F 50-CAGGATGAAATGAGGCTTGAGC-30,
R 50-TTAGGGAAGAGAGATGGGGTGTGG-30), and GAPDH
(F 50-GCTCAGACACCATGGGGAAGGT-30, R 50-GTGGTGCAGG
AGGCATTGCTGA-30). All reactions were carried out and analyzed
using the CFX96 real-time PCR system (Bio-Rad, Hercules, CA,
USA). The expression of GAPDH mRNA in each sample was used019
www.moleculartherapy.orgto normalize the data. Relative gene expression was analyzed by
2DDCt method.
Identification of cIN Maturation-Specific Rank-Based
Differences in Gene Expression
To identify transcriptome changes during cIN maturation, we
compared the transcriptome of puriﬁed cINs in the E13 mice cortex28
versus puriﬁed cINs in the P40 mice cortex.29 All MoGene 1.0 ST
arrays28 were processed using the “oligo” BioConductor package47
and all mouse 430A2 arrays29 with the “affy” Bioconductor package.48
Both the E13 cortex and P40 interneurons’ array data were quality
controlled with array Quality Metrics,49 normalized with multi-array
average (RMA),50 ﬁltered, subset to one probe per gene (using the
probeset for each gene with the maximummean value for all samples)
and further subset to common genes between two datasets using the
insilicodb Bioconductor package.51 Due to difference in the probe in-
tensity distributions of the two arrays in the studies, we compared
gene expression via a rank-based method. In brief, rank-based anal-
ysis was performed as follows: expression intensities for each gene
were ranked within each sample and squared. The mean squared
ranks for a study were then compared to ﬁnd genes with the high
expression in adults and low expression in embryonic samples.
Pathways enriched after cIN maturation (rank difference > 3,000)
were identiﬁed using DAVID (https://david.ncifcrf.gov/).
Oxidative Phosphorylation Analysis Using Seahorse Analyzer
Mitochondrial activity of cINs was measured using the seahorse XFp8
analyzer (Agilent Technologies, Santa Clara, CA, USA) according to
the manufacturer’s instructions. In brief, cells were plated in the XF
cell culture miniplate and incubated at 37C with 5% CO2. One day
before the test, the cartridge with XF calibrant was incubated in a
non-CO2 incubator overnight to equilibrate. Before the assay, the
media was changed to XF assay medium supplemented with 5 mM
sodium pyruvate (Thermo Fisher, Waltham, MA, USA), 10 mM
glucose (Thermo Fisher, Waltham, MA, USA), and 2 mM glutamine
and equilibrated in a non-CO2 incubator for 1 h. Oxygen consump-
tion rates (OCRs) were monitored through sequential injections of
1 mM oligomycin, 0.3 mM carbonyl cyanide 4-(triﬂuoromethoxy)
phenylhydrazone (FCCP), and 1 mM rotenone/antimycin A (seahorse
XF cell mito stress test kit, Agilent, Santa Clara, CA, USA). Raw
data were used to calculate the various parameters of the mitochon-
drial activity: basal respiration = baseline OCR-rotenone/antimycin
A OCR; ATP production = baseline OCR-oligomycin OCR;
maximum respiration = FCCP OCR-rotenone/antimycin A OCR;
and spare capacity = maximum respiration-basal respiration. The
result was normalized to total protein levels quantiﬁed using a
bicinchoninic acid (BCA) protein assay (Thermo Fisher, Cambridge,
MA, USA).
cINs Migration and Arborization Analysis In Vitro
For in vitro migration analysis, 9-week-old cIN spheres were
embedded in Geltrex matrix and treated with or without CDP for
7 days. Phase pictures were taken on day 0 and day 7 after embedding
to follow migration of cINs. For quantiﬁcation of migrated cells, theMoleculembedded spheres were incubated with Hoechst (Sigma-Aldrich,
Natick, MA, USA) overnight on day 7, and the entire embedding
was imaged and tiled for Hoechst signal and used for cell counting
using the multi-point function in ImageJ software. Cell numbers
within sphere core, in migration distance 0–400 mm, and in distance
longer than 400 mm were counted separately for each sphere.
For arborization analysis, the MGE progenitors were plated onto the
PLO/FN-coated coverslips after 3 weeks’ differentiation with or
without CDP. Two weeks later, the MGE cells were infected with
limiting titer (MOI, 0.001) of LV-UbiC-GFP virus52 to label cells
only scarcely. One week after infection, the images of GFP+ cells
were collected by the EVOS microscope. The arborization of each
GFP+ cell was analyzed using ImageJ software with the Neuron J plu-
gin to get parameters of total neurite length, total branch number, and
neurite number from soma.
Electrophysiological Analysis In Vitro
Three-week-old MGE progenitor cells were cocultured on PF-coated
coverslips with rat cortical astroglial cells (PC36108, Neuromics,
Edina, MN, USA) at a ratio of 5:1 and in B27GB media supplemented
with 1.8 mM CaCl2. cINs were then infected with a LV-Syn-Chr2-
YFP virus (plasmid #20945, Addgene, Cambridge, MA, USA) and
maintained with or without CDP treatment for 9 weeks. At 12 weeks,
cINs were transferred into a recording submersion chamber, which
was continuously perfused at room temperature (21C –23C) at
a ﬂow rate of 1.5–2 mL/min with artiﬁcial cerebrospinal ﬂuid
(130 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl2, 1 mM MgSO4,
1.25 mM NaH2PO4, 26 mM NaHCO3, and 10 mM glucose) with
an osmolarity of 295–305 mM, gassed continuously with 5%
CO2/95% O2. Whole-cell patch-clamp recordings were acquired
with a Multiclamp 700B (Axon Instruments, Molecular Devices,
San Jose, CA, USA), Digidata 1550 (Axon Instruments, Molecular
Devices, San Jose, CA, USA), and Clampex 10 software (Molecular
Devices, San Jose, CA, USA). Whole-cell patch-clamp electrodes
(3–5 mU resistance) were ﬁlled with an intracellular solution
containing in mM: 120 K-gluconate, 9 KCl, 10 KOH, 8 NaCl, 10
HEPES, 3.48 MgATP, 0.4 Na3GTP, 17.5 sucrose, 0.5 EGTA, with
an osmolarity of290 and pH 7.3. Sampling was done at 5 kHz unless
speciﬁed otherwise. Liquid junction potential of 9.7 mVwas corrected
for the internal pipette solution used. RMP was recorded at I = 0. To
compare membrane excitability, membrane potential was held at
70mV and square pulses of depolarizing current steps were applied
in current clamp mode (10 to80 pA in increments of 10 pA, 0.8 s
duration). The ﬁrst AP induced by depolarizing current was used to
analyze AP threshold, AHP amplitude, and AP half-width, using
Clampﬁt software (Molecular Devices, San Jose, CA, USA). Cm was
calculated with the membrane test function on Clampex 10, using a
5 mV voltage pulse from the holding voltage of70mV and recorded
currents in voltage-clamp mode with a sampling rate of 100 kHz. Rm
was calculated in current clamp mode by applying a 10 pA current
step and using the steady-state voltage deﬂection to calculate Rm as
(steady-state voltage deﬂection/10 pA). Averages ± SEM are repre-
sented in Figures 5 and S5B.ar Therapy: Methods & Clinical Development Vol. 13 June 2019 427
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After treated with or without CDP for 3 weeks, the electrophysiology
analysis was performed as described above. Averages ± SEM of these
cells are represented in Figure S5C.
Transplantation and Immunohistochemistry Analysis
All animal procedures were carried out in accordance with the
approved guidelines and all animal protocols were approved by the
Institutional Animal Care and Use Committee at New York Medical
College. The cINs were trypsinized and plated on a PLO/FN plate at
the density of 105/cm2 at the end of 3 weeks’ differentiation. After
1 week’s CDP treatment, the cINs were trypsinized and resuspended
in transplantation media (Hank’s balanced salt solution [HBSS] with
4.5 mg/mL sucrose, 10 ng/mL GDNF, 10 ng/mL BDNF, 20 nM Boc-
Asp(OMe) ﬂuoromethyl ketone [BAF; Sigma-Aldrich, Natick, MA,
USA], and 10 mM rock inhibitor at a density of 1  105/mL). A
1-mL volume of cINs were injected into the cortices of Nod Scid
mice (Charles River Laboratory, Kingston, NY, USA) using a Kopf
stereotaxic instrument (Kopf, Tujunga, CA, USA) with a mouse
adaptor (Stoelting, Wood Dale, IL, USA) under isoﬂurane anesthesia
(3% induction, followed by 1% maintenance). The cells were injected
at each of the following coordinates: AP 0.00 mm, L ± 3.28 mm, V
1.80 mm; AP 2.12 mm, L ± 4.20 mm, V 2.00 mm. One month
after transplantation, the mice were perfused with 0.1M PBS followed
by 4% PFA. The brains were removed and postﬁxed in 4% PFA
solutions overnight and then placed in 30% sucrose solutions for
1 day. Forty-micrometer-thick coronal sections were cut on a Leica
CM1850 cryostat (Leica Biosystem, Buffalo Grove, IL, USA). The
immunohistochemistry process followed the same procedure as
immunocytochemistry as described above. The antibodies used are
summarized in Table S2. Images were captured and analyzed by
EVOS FL auto microscope (Life Technologies, Carlsbad, CA, USA)
and Zeiss LSM710 confocal laser scanning microscopes (Zeiss, Ober-
kochen, Gremany).
For in vivo migration analysis, human-speciﬁc NCAM/DAPI images
of areas including more than 500 mm around the graft were captured
and tiled using Zeiss LSM710 confocal laser scanning microscopes
with 10 objective, and grafted cell numbers were counted using
the multi-point function in ImageJ software. Grafted cells in the graft
cores, in migration distance of 0–100 mm and in migration distance
longer than 100 mm were counted separately for each graft.
For synapse analysis, images were captured using Zeiss LSM710
confocal laser scanning microscopes (Zeiss, Oberkochen, Gremany)
with 100 objective and processed using IMARIS software (Bitplane,
Switzerland), which allows objective counting of synaptic puncta
based upon absolute ﬂuorescent intensity. Synaptic puncta positive
for VGAT (inhibitory presynaptic) and Gephyrin (inhibitory post-
synaptic) were identiﬁed with spot diameters of 0.6 mm. For synapses,
a juxtaposition of hNCAM+VGAT+ puncta and Vglut1+ puncta was
determined as inhibitory synapses. The result was expressed as
synapse numbers per human NCAM+ neuronal surface area (mm2).
We analyzed a total of 795 neurite segments with a total area of428 Molecular Therapy: Methods & Clinical Development Vol. 13 June 27,442 mm2 for control cINs and a total of 977 neurite segments
with a total area of 7,442 mm2 for CDP-treated cINs. Total counted
colocalized puncta numbers are 37 for control cINs and 161 for
CDP-treated cINs.
Statistics
The statistical analysis was performed using GraphPad Prism7
(GraphPad Software, La Jolla, CA, USA). A two-tailed, unpaired t
test was used to compare the difference between two groups.
One-way ANOVA was used to compare the difference among multi-
ple groups, and once a signiﬁcant difference was observed, Tukey
post-hoc test was performed to compare the difference between any
two groups. When p < 0.05, the difference was considered as statisti-
cally signiﬁcant.
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